Fabrice Barlesi, MD

Fabrice Barlesi, MD, head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Aix-Marseille University and the Assistance Publique H&ocirc;pitaux de Marseille, France, discusses the importance of molecular testing in patients with nonsquamous nonsmall cell lung cancer (NSCLC)&nbsp;during the&nbsp;World Conference on Lung Cancer&nbsp;(WCLC)&nbsp;in Toronto, Canada.

In this patient population, Barlesi recommends testing for at least 4 biomarkers, including EGFR, ALK, ROS1, and BRAF. He says there are now clear signs of&nbsp;efficacy with additional biomarkers, as well.

Barlesi says results were presented at this year&rsquo;s WCLC meeting for&nbsp;patients withRET, NTRK, and TRK rearrangements. The field continues to grow rapidly&nbsp;with many approved drugs,&nbsp;as well some&nbsp;that have received a breakthroughdesignation from the FDA.

Videos

Fabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non&ndash;small cell lung cancer during the&nbsp;World Conference on Lung Cancer in Toronto, Canada.

Fabrice Barlesi, MD | Authors

Articles

Molecular Profiling in NSCLC